{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T05:20:21Z","timestamp":1701408021454},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The benefit of surfactant replacement therapy for respiratory distress syndrome (RDS) has been demonstrated. However, some surfactants are expensive and usually inaccessible. Consequently, the Iranian Survanta was produced, but its effect on complications and mortality of RDS is unknown. This study aimed to compare the therapeutic outcomes of Iranian surfactant (beraksurf) and BLES (bovine lipid extract surfactant) on RDS treatment among preterm neonates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This triple blinded randomized controlled trial study was performed on 128 eligible neonates diagnosed with RDS in Afzalipour hospital in Kerman, Iran. Diagnosis of RDS, gestational age of 28\u201334 weeks and weight\u2009\u2265\u20091\u00a0kg were considered as inclusion criteria. Congenital anomalies such as congenital cyanotic heart diseases, digestive system anomalies and chromosome abnormalities were the exclusion criteria Neonates were randomly assigned into two equal groups: (1) those treated with BLES (n\u2009=\u200964) and (2) those treated with beraksurf (n\u2009=\u200964). Complications including patent ductus arteriosus (PDA), sepsis, intraventricular hemorrhage (IVH), pneumothorax, pulmonary hemorrhage, mortality, and also, the number of days required for invasive mechanical ventilation (using ventilator) and non-invasive continuous positive airway pressure (CPAP) were evaluated for all neonates. The risk ratio (RR) was calculated at 95% of confidence intervals (CI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with BLES group, the RR estimate among neonates in beraksurf group was 0.89 (0.66\u20131.20) for PDA, 0.71 (0.23\u20132.13) for IVH, 0.44 (0.14\u20131.36) for sepsis, 0.35 (0.13\u20130.93) for pneumothorax, 0.33 (0.12\u20130.86) for pulmonary hemorrhage, and 0.55 (0.28\u20131.05) for mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite advances in the use of exogenous surfactants for the treatment of neonatal respiratory distress syndrome; There are still some controversial topics in this field. The results obtained in the present study showed that the two types of surfactant (BERAKSURF and BLES) have similar efficacy for the treatment and short-term outcomes in preterm infants with respiratory distress syndrome. Therefore, due to the cost-effectiveness of BRAKSURF compared to BLES, We recommend choosing BERAKSURF in terms of treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-023-04406-2","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T03:02:23Z","timestamp":1701399743000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the efficacy of two natural surfactants (BERAKSURF and BLES) in the treatment of respiratory distress syndrome among preterm neonates"],"prefix":"10.1186","volume":"23","author":[{"given":"Fatemeh","family":"Sabzevari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdie","family":"Eslamian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Karami Robati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahareh","family":"Bahmanbijari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Daei Parizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"issue":"9","key":"4406_CR1","first-page":"724","volume":"20","author":"M Chi","year":"2018","unstructured":"Chi M, Mei YB, Feng ZC. [A review on neonatal acute respiratory distress syndrome]. Zhongguo Dang Dai Er Ke Za Zhi = Chinese. J Contemp Pediatr. 2018;20(9):724\u20138.","journal-title":"J Contemp Pediatr"},{"issue":"4","key":"4406_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1159\/000499361","volume":"115","author":"DG Sweet","year":"2019","unstructured":"Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, et al. European Consensus guidelines on the management of respiratory distress syndrome \u2013 2019 update. Neonatology. 2019;115(4):432\u201350.","journal-title":"Neonatology"},{"issue":"1","key":"4406_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5334\/aogh.2739","volume":"86","author":"KAA Baseer","year":"2020","unstructured":"Baseer KAA, Mohamed M, Abd-Elmawgood EA. Risk factors of Respiratory Diseases among neonates in neonatal intensive care unit of Qena University Hospital, Egypt. Ann Glob Health. 2020;86(1):22.","journal-title":"Ann Glob Health"},{"issue":"4","key":"4406_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00408-013-9475-3","volume":"191","author":"H Sun","year":"2013","unstructured":"Sun H, Xu F, Xiong H, Kang W, Bai Q, Zhang Y, et al. Characteristics of respiratory distress syndrome in infants of different gestational ages. Lung. 2013;191(4):425\u201333.","journal-title":"Lung"},{"key":"4406_CR5","first-page":"Cd005254","volume":"7","author":"A Aziz","year":"2012","unstructured":"Aziz A, Ohlsson A. Surfactant for pulmonary haemorrhage in neonates. Cochrane Database Syst Rev. 2012;7:Cd005254.","journal-title":"Cochrane Database Syst Rev"},{"key":"4406_CR6","unstructured":"Behrman RKR. Nelson Essentials of Pediatrics. WB Saunders, Philadelphia. 2011;2nd Edition."},{"issue":"25","key":"4406_CR7","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.3346\/jkms.2019.34.e175","volume":"34","author":"CW Bae","year":"2019","unstructured":"Bae CW, Kim CY, Chung SH, Choi YS. History of pulmonary surfactant replacement therapy for neonatal respiratory distress syndrome in Korea. J Korean Med Sci. 2019;34(25):e175\u2013e.","journal-title":"J Korean Med Sci"},{"issue":"32","key":"4406_CR8","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.3346\/jkms.2020.35.e253","volume":"35","author":"JE Shin","year":"2020","unstructured":"Shin JE, Yoon SJ, Lim J, Han J, Eun HS, Park MS, et al. Pulmonary surfactant replacement therapy for respiratory distress syndrome in neonates: a Nationwide Epidemiological Study in Korea. J Korean Med Sci. 2020;35(32):e253.","journal-title":"J Korean Med Sci"},{"issue":"6","key":"4406_CR9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1651-2227.2005.tb01984.x","volume":"94","author":"C Ann Malloy","year":"2005","unstructured":"Ann Malloy C, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr. 2005;94(6):779\u201384.","journal-title":"Acta Paediatr"},{"key":"4406_CR10","doi-asserted-by":"crossref","unstructured":"Dizdar EA, Sari FN, Aydemir C, Oguz SS, Erdeve O, Uras N et al. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome. Am J Perinatol. 2011:95\u2013100.","DOI":"10.1055\/s-0031-1295648"},{"key":"4406_CR11","unstructured":"Martin RJ, Fanaroff AA, Walsh MC. Fanaroff and Martin\u2019s neonatal-perinatal medicine e-book: diseases of the fetus and infant. Elsevier Health Sciences; 2019."},{"issue":"3","key":"4406_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/s-2004-823779","volume":"21","author":"R Ramanathan","year":"2004","unstructured":"Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K. A randomized, multicenter masked comparison trial of poractant alfa (curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol. 2004;21(3):109\u201319.","journal-title":"Am J Perinatol"},{"key":"4406_CR13","doi-asserted-by":"crossref","unstructured":"Cond\u00f2 V, Cipriani S, Colnaghi M, Bell\u00f9 R, Zanini R, Bulfoni C et al. Neonatal respiratory distress syndrome: are risk factors the same in preterm and term infants? The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2017;30(11):1267\u201372.","DOI":"10.1080\/14767058.2016.1210597"},{"issue":"2","key":"4406_CR14","first-page":"469","volume":"31","author":"M Mirzarahimi","year":"2018","unstructured":"Mirzarahimi M, Barak M. Comparison efficacy of Curosurf and Survanta in preterm infants with respiratory distress syndrome. Pak J Pharm Sci. 2018;31(2):469\u201372.","journal-title":"Pak J Pharm Sci"},{"issue":"4","key":"4406_CR15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1542\/peds.107.4.642","volume":"107","author":"M Vento","year":"2001","unstructured":"Vento M, Asensi M, Sastre J, Garc\u00eda-Sala F, Pallard\u00f3 FV, Vi\u00f1a J. Resuscitation with room air instead of 100% oxygen prevents oxidative stress in moderately asphyxiated term neonates. Pediatrics. 2001;107(4):642\u20137.","journal-title":"Pediatrics"},{"issue":"6","key":"4406_CR16","doi-asserted-by":"publisher","first-page":"L1222","DOI":"10.1152\/ajplung.00230.2001","volume":"282","author":"HJ Rozycki","year":"2002","unstructured":"Rozycki HJ, Comber PG, Huff TF. Cytokines and oxygen radicals after hyperoxia in preterm and term alveolar macrophages. Am J Physiol Lung Cell Mol Physiol. 2002;282(6):L1222\u20138.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"Suppl 2","key":"4406_CR17","first-page":"455","volume":"85","author":"T Kolatat","year":"2002","unstructured":"Kolatat T, Aunganon K, Yosthiem P. Airway Complications in neonates who received mechanical ventilation. J Med Association Thailand = Chotmaihet Thangphaet. 2002;85(Suppl 2):455\u201362.","journal-title":"J Med Association Thailand = Chotmaihet Thangphaet"},{"issue":"2","key":"4406_CR18","doi-asserted-by":"publisher","first-page":"L379","DOI":"10.1152\/ajplung.00176.2004","volume":"288","author":"M Rudiger","year":"2005","unstructured":"Rudiger M, Tolle A, Meier W, Rustow B. Naturally derived commercial surfactants differ in composition of surfactant lipids and in surface viscosity. Am J Physiology-Lung Cell Mol Physiol. 2005;288(2):L379\u2013L83.","journal-title":"Am J Physiology-Lung Cell Mol Physiol"},{"key":"4406_CR19","doi-asserted-by":"publisher","first-page":"102061","DOI":"10.1016\/j.cis.2019.102061","volume":"275","author":"R Jahan","year":"2020","unstructured":"Jahan R, Bodratti AM, Tsianou M, Alexandridis P. Biosurfactants, natural alternatives to synthetic surfactants: physicochemical properties and applications. Adv Colloid Interface Sci. 2020;275:102061.","journal-title":"Adv Colloid Interface Sci"},{"issue":"3","key":"4406_CR20","first-page":"161","volume":"11","author":"KE Corff","year":"2006","unstructured":"Corff KE, Greubel S, McCann DL, Williams R, Varner DL. Practical considerations in the selection and use of pulmonary surfactant therapy for neonatal respiratory distress syndrome in the intensive care setting. J Pediatr Pharmacol Therapeutics: JPPT : Official J PPAG. 2006;11(3):161\u20138.","journal-title":"J Pediatr Pharmacol Therapeutics: JPPT : Official J PPAG"},{"issue":"5","key":"4406_CR21","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.4103\/jfmpc.jfmpc_188_17","volume":"7","author":"AA Macooie","year":"2018","unstructured":"Macooie AA, Fakour Z, Roanaghi P. Comparative evaluation of the effects of BLES and Survanta on treatment of respiratory distress syndrome in newborns. J Family Med Prim Care. 2018;7(5):1063\u20137.","journal-title":"J Family Med Prim Care"},{"key":"4406_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.conctc.2016.04.003","volume":"3","author":"B Najafian","year":"2016","unstructured":"Najafian B, Karimi-Sari H, Khosravi MH, Nikjoo N, Amin S, Shohrati M. Comparison of efficacy and safety of two available natural surfactants in Iran, Curosurf and Survanta in treatment of neonatal respiratory distress syndrome: a randomized clinical trial. Contemp Clin Trials Commun. 2016;3:55\u20139.","journal-title":"Contemp Clin Trials Commun"},{"issue":"5","key":"4406_CR23","first-page":"e5743","volume":"26","author":"M Mussavi","year":"2016","unstructured":"Mussavi M, Mirnia K, Asadollahi K. Comparison of the efficacy of three natural surfactants (Curosurf, Survanta, and Alveofact) in the treatment of respiratory distress syndrome among neonates: a Randomized Controlled Trial. Iran J Pediatr. 2016;26(5):e5743\u2013e.","journal-title":"Iran J Pediatr"},{"issue":"5","key":"4406_CR24","first-page":"738","volume":"20","author":"N Hashemian","year":"2014","unstructured":"Hashemian N, Aldaghi M, Vafaeifard E, Rakhshani M, Hosseini B. Comparing the Effect of different types of surfactant on the treatment of respiratory distress in Preterm neonates admitted to NICU of Mobini Hospital of Sabzevar, in 2009\u20132010. Q J Sabzevar Univ Med Sci. 2014;20(5):738\u201346. (In Persian).","journal-title":"Q J Sabzevar Univ Med Sci"},{"issue":"2","key":"4406_CR25","first-page":"76","volume":"18","author":"Y Minoo Fallahi","year":"2013","unstructured":"Minoo Fallahi Y, Samizadeh. Mahta Fatemeh Bassir. Assessing the role of curosurf and survanta in prognosis of neonatal RDS. Pajoohande. 2013;18(2):76\u201382. (In Persian).","journal-title":"Pajoohande"},{"issue":"7","key":"4406_CR26","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s12098-010-0097-y","volume":"77","author":"MM Gharehbaghi","year":"2010","unstructured":"Gharehbaghi MM, Sakha SH, Ghojazadeh M, Firoozi F. Complications among premature neonates treated with beractant and poractant alfa. Indian J Pediatr. 2010;77(7):751\u20134.","journal-title":"Indian J Pediatr"},{"issue":"6","key":"4406_CR27","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1651-2227.2005.tb01984.x","volume":"94","author":"CA Malloy","year":"2005","unstructured":"Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr (Oslo Norway: 1992). 2005;94(6):779\u201384.","journal-title":"Acta Paediatr (Oslo Norway: 1992)"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-023-04406-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-023-04406-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-023-04406-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T03:03:50Z","timestamp":1701399830000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-023-04406-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4406"],"URL":"https:\/\/doi.org\/10.1186\/s12887-023-04406-2","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance to the Declaration of Helsinki. The ethics committee of Kerman University of medical sciences approved this study (Code: IR.KMU.AH.REC.1400.012). In addition, this study was approved by the Iranian Registry of Clinical Trials (IRCT) (Code: IRCT20210501051148N1) in 11\/07\/2021. Written informed consent was obtained from parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors of this study claim no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"608"}}